



CompuGroup Medical SE & Co. KGaA

Contact for media representatives:

Dr. Thomas Speckmann
Global Head of Communications
M: +49 151 29282247
E-Mail: thomas.speckmann@cgm.com

Web: www.cgm.com

Social Media: Visit us on [Facebook](#), [X](#), [LinkedIn](#) und [XING](#)

Contact for analysts and investors:

Claudia Thomé
Senior Vice President Investor Relations
M: +49 160 3630362
E-Mail: claudia.thome@cgm.com

Press Release, November 7, 2024

CGM drives innovation in the third quarter while recording earnings decline with almost stable revenues

Koblenz - CompuGroup Medical, one of the world's leading e-health providers, recorded revenues of EUR 283.4 million in the third quarter of the 2024 financial year, slightly (-1 percent) below the previous year's level (PY: EUR 285.7 million), which is attributable to high one-off effects in the previous year. At EUR 70 million, one-time revenues were 16 percent below the prior year (PY: EUR 83.5 million). Recurring revenues increased by 6 percent to EUR 213.5 million (PY: EUR 202.2 million). The share of recurring revenues increased by 4 percentage points and now accounts for 75 percent of total revenues.

In the same period, adjusted EBITDA declined by 12 percent to EUR 54.9 million (PY: EUR 62.2 million). The EBITDA margin stood at 19 percent (PY: 22 percent). In addition to the decline in revenues, this is mainly due to investments in innovative products and solutions. Expenses for research and development rose year-on-year from EUR 60.0 million to EUR 62.4 million in the third quarter. CompuGroup Medical once again demonstrated its innovative capabilities by launching new solutions and modules. These include the CGM ONE telephone assistant, an AI-based co-pilot module for German medical practices, and CGM

CompuGroup Medical SE & Co. KGaA · Maria Trost 21 · 56070 Koblenz · T +49 261 8000-0 · F +49 261 8000-1166 · www.cgm.com
Chairman of the Supervisory Board: Philipp von Ilberg · Company domiciled in: Koblenz, HRB 27430, Local Court Koblenz

General Partner: CompuGroup Medical Management SE · Company domiciled in: Koblenz, HRB 27343, Local Court Koblenz
Chairman: Frank Gotthardt

Managing Directors: Prof. (apl.) Dr. med. Daniel Gotthardt (CEO), Daniela Hommel, Emanuele Mugnani, Hannes Reichl, Dr. Ulrich Thomé
VAT ID: DE114134699 · Commerzbank Koblenz · Bank Code: 570 400 44 · Bank Account Number: 208 002 600 · IBAN: DE60 5704 0044 0208 0026 00 · BIC: COBADEFFXXX



STELLA, the first cloud-based pharmacy software, also in combination with ASK STELLA, an AI-assisted module for pharmacy customers.

Adjusted earnings per share amounted to EUR 0.35 in the third quarter of 2024 (PY: EUR 0.43). Free cash flow increased by EUR 9.6 million to EUR 17.3 million compared to the prior year. Net debt amounted to EUR 777.0 million at the end of September 2024, compared to EUR 702.5 million at the end of December 2023.

In the **Ambulatory Information Systems (AIS)** segment, revenues in the third quarter of 2024 amounted to EUR 172.8 million, slightly above the prior year figure of EUR 171.7 million. Recurring revenues increased by 5 percent to EUR 133.0 million (PY: EUR 127.0 million). The share of recurring revenues rose from 74 percent in the same quarter of the previous year to 77 percent.

Revenues in the **Hospital Information Systems (HIS)** segment declined by 4 percent to EUR 76.6 million in the third quarter of 2024 (PY: EUR 79.6 million), mainly due to high one-off revenues in the same period of the previous year. Recurring revenues increased by 8 percent to EUR 56.6 million (PY: EUR 52.2 million). The share of recurring revenues in segment revenues rose from 66 percent to 74 percent.

In the **Pharmacy Information Systems (PCS)** segment, revenues in the third quarter of 2024 fell by 1 percent to EUR 34.0 million (PY: EUR 34.5 million), which was also primarily due to high non-recurring revenues in the previous year. Recurring revenues in the PCS segment increased by 4 percent to EUR 23.9 million (PY: EUR 23.0 million). The share of recurring revenues in segment revenues increased from 67 percent to 70 percent.

CGM had revised its guidance for the financial year 2024 on July 9 as follows: Organic revenue development (adjusted for acquisitions and currency effects) is expected to be in a range between -2 percent and 0 percent year-on-year (previously +4 % and +6 %). Adjusted EBITDA



is expected to be in a range between EUR 220 million and EUR 250 million (previously EUR 270 million and EUR 310 million).

The full financial report as of September 30, 2024 is available for download at www.cgm.com/ir-publications.

About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies in the world. With a revenue base of EUR 1.19 billion in 2023, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories, hospitals and social welfare institutions. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. The basis of CompuGroup Medical's services is its unique customer base, including doctors, dentists, pharmacists and other healthcare professionals in inpatient and outpatient facilities, as well as insurance and pharmaceutical companies. CompuGroup Medical has offices in 19 countries and offers its solutions in 60 countries worldwide. More than 8,700 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.